License Revenue (Details)	12 Months Ended
	Dec. 31, 2020 USD ($)
License Agreement Terms [Member]
Gross up-front license fee	$ 6,000,000
Aggregate licence payment received	$ 14,000,000
Description of licensing agreement	The Company will supply lenzilumab to the Licensee for a minimum of 7.5 years at a cost-plus basis from an existing or future manufacturer.
Revenue recognized performance obligation description of payment	Over the 29-month period through March of 2023 (the “Performance Period”), the expected period over which the Company conservatively expects the Services to be performed with approval in the Territory expected by the end of March 2023.
License revenue	$ 300,000
Up-front Payment Arrangement [Member]
Upfront payment	$ 4,500,000